ETC-1002 · Nexletol, ESP-55016

What is ETC-1002?

Bempedoic acid (Nexletol) is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers LDL cholesterol by inhibiting cholesterol synthesis in the liver.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Nexletol, ESP-55016

Drug type

Small molecule

Targets

adenosine triphosphate-citrate lyase (ACLY)

Mechanism

Inhibitor of adenosine triphosphate-citrate lyase (ACLY)

Pathways

cholesterol biosynthesis, LDL-C lowering

Therapy area

Cardiovascular, Metabolic

Developer

Esperion Theraps Inc

In trials of

MEDP

FDA status

Approved as Nexletol (February 21, 2020), NDA211616 · FDA label

UNII

1EJ6Z6Q368

✅ FDA-approved uses

• Reduction of major adverse cardiovascular events in adults at increased risk unable to take statin therapy
• Reduction of LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia

From the indications section of the FDA label (version of Jun 25, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HypercholesterolemiaHypertension

Sources

• FDA label (DailyMed)
• FDA label Nexletol (2026-06-25), indications
• ClinicalTrials.gov NCT02178098

Updated Oct 3, 2026.